Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Transitioning regimen may prolong proteasome inhibitor–based therapy for MM
Key clinical point: Transitioning from parenteral bortezomib-based induction to all-oral ixazomib-lenalidomide-dexamethasone increased proteasome inhibitor–based treatment adherence/duration.
Major finding: Overall response rate was 62% after bortezomib-based induction, and 70% after induction to all-oral ixazomib-lenalidomide-dexamethasone.
Study details: US MM-6 is a community-based, real-world, open-label, single-arm, phase 4 study, which at data cutoff had 84 patients treated.
Disclosures: The study was sponsored by Millennium Pharmaceuticals. Four of the authors are employees of Millennium Pharmaceuticals and several authors disclosed relationships with various pharmaceutical companies, including Millennium Pharmaceuticals.
Manda S et al. Clin Lymphoma Myeloma Leuk. 2020 Jun 30. doi: 10.1016/j.clml.2020.06.024.